Levetiracetam Desitin (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a crucial role in neurotransmitter release. This binding modulates vesicle exocytosis, leading to decreased neuronal excitability and suppression of abnormal electrical activity that triggers seizures.

The dosage of levetiracetam is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate infusion rate and total daily amount according to clinical guidelines and patient response.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss risks and alternatives with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levetiracetam is distinguished by its unique SV2A binding mechanism, minimal hepatic metabolism, and a relatively low potential for drug‑drug interactions compared with many older antiepileptics. This profile often makes it a preferred option when polypharmacy or hepatic impairment is a concern.

Levetiracetam Desitin should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the product, and ensure the vial is kept upright to avoid agitation of the solution.

Levetiracetam Desitin is administered intravenously by a healthcare professional. The solution is typically diluted in a compatible IV fluid and infused over a period determined by the prescriber, ensuring aseptic technique and proper monitoring during administration.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, blood dyscrasias, and the emergence of suicidal thoughts or severe depression. Patients should be monitored closely for any signs of these conditions, and immediate medical attention is required if they occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled psychiatric disorders, or those taking medications that may significantly reduce its effectiveness.